Advanced Micro Devices IncLeadership in server CPUs for agentic AI and record desktop CPU revenue share driving growth.
Moderna, Krystal Biotech, and Advanced Micro Devices have significantly outperformed the broader market this year, and each still holds further upside potential. Moderna shares are up 100% year to date as the company nears potential approval for its influenza vaccine mRNA-1010 and advances a pipeline that includes a personalized cancer vaccine in phase 2 and phase 3 trials. Krystal Biotech has gained 38% this year, driven by Vyjuvek, the first FDA-approved gene therapy for dystrophic epidermolysis bullosa, with a large addressable market still untapped in Europe and elsewhere plus over half a dozen pipeline candidates. AMD has soared 129% year to date, benefiting from its leadership in server CPUs critical for agentic AI and a record 46.2% revenue share in desktop CPUs, positioning it to keep riding the AI wave.
Advanced Micro Devices IncLeadership in server CPUs for agentic AI and record desktop CPU revenue share driving growth.
NVIDIA Corporation
Krystal Biotech IncVyjuvek is first FDA-approved gene therapy for dystrophic epidermolysis bullosa, with untapped European market.
Moderna IncNear potential approval for influenza vaccine mRNA-1010 and advancing personalized cancer vaccine pipeline.
Intel Corporation